SZKJT(San-Zhong-Kui-Jian-Tang)
Phase 1Small molecule
SZKJT(San-Zhong-Kui-Jian-Tang) is one of 18 small molecule programs targeting Oral Cavity Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Oral Cavity Cancer
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Decadron
AAspen Global Incorporated
Approved
Vectibix
AmgenPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Trexall
Alnylam PharmaceuticalsPhase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Tarceva
DDutch Society of Physicians for Pulmonology and Tuberculosis
Phase 2
PF-00299804
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oral Cavity Cancer1 trial
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
Completed·—·Phase 1·NCT05590650·21 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details